Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
November 2013, Vol 4, No 9
November 2013, Vol 4, No 9
Community Oncology Care Improves Outcomes, Adds Value in the New Models of Cancer Care
Community Oncology
November 2013, Vol 4, No 9
Hollywood, FL—As new models of oncology care evolve, they should not dismiss the importance of multidiscipline involvement, Thomas A. Marsland, MD, President, Integrated Community Oncology Network, Orange Park, FL, maintained in his talk at the 3rd Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Recent Surveys Highlight Ongoing Challenges for Oncology Practices
By
Caroline Helwick
November 2013, Vol 4, No 9
Hollywood, FL—Many current forces are colliding to challenge community oncology, according to David Eagle, MD, Immediate Past President of Community Oncology Alliance (COA), Lake Norman Oncology, Mooresville/Huntersville, NC. At the 3rd Annual Conference of the Association for Value-Based Cancer Care, Dr Eagle described the seriousness of the plight faced by community oncology practices.
Read Article
Can FDA Drug Approval Keep Pace with Translational Research?
By
Audrey Andrews
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
With the development of targeted therapies, there has been a clear evolution in the pathway to the approval of drugs by the US Food and Drug Administration (FDA), and a rapid approval of a drug after phase 1 clinical trials, which show definitive proof of activity and safety, and “breakthrough” designation, are now possible.
Read Article
PET Use for NSCLC Management Has Altered Resource Utilization, Increased Cost
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
Atlanta, GA—The adoption of positron emission tomography (PET) imaging for the management of patients with non–small-cell lung cancer (NSCLC) has had a mixed impact on clinical and economic outcomes, according to findings from a large retrospective cohort study.
Read Article
Panel Recommends Major Changes for Cutting Down Cancer Overdiagnosis and Overtreatment
By
Eileen Koutnik-Fotopoulos
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
For the past 30 years, awareness and screening have led to an emphasis on the early diagnosis of cancer. The goals were to get screened and to catch cancer early to reduce the rate of late-stage disease and to decrease cancer mortality.
Read Article
Cost-Effective Strategy for Early NSCLC Hinges on Operability of the Disease
By
Charles Bankhead
Economics & Value
,
Economics of Cancer Care
November 2013, Vol 4, No 9
Surgery and stereotactic body radiotherapy (SBRT) proved cost-effective strategies for stage I non–small-cell lung cancer (NSCLC) when applied to specific patient populations, according to a study reported at the 2013 American Society for Radiation Oncology meeting.
Read Article
ASCO’s “Choosing Wisely” Top 5 List: Inappropriate Tests, Imaging, and Targeted Therapies
By
Charles Bankhead
ASCO Quality Care Symposium
,
ASCO
November 2013, Vol 4, No 9
Unnecessary treatment, imaging, and testing all came into focus in the American Society of Clinical Oncology (ASCO)’s 2013 choices for the Choosing Wisely campaign to eliminate the overuse and misuse of medical care resources.
Read Article
Development of Quality Measures Should Address Current Limitations
By
Charles Bankhead
ASCO Quality Care Symposium
,
ASCO
November 2013, Vol 4, No 9
A new sense of urgency surrounds the need to improve quality measurement, even as major gaps persist in existing measures, said Jennifer L. Malin, MD, PhD, Medical Director, Oncology, WellPoint, at the 2013 ASCO Quality Care Symposium.
Read Article
Integrating Patient-Reported Outcomes into Cancer Care
By
Charles Bankhead
ASCO Quality Care Symposium
,
ASCO
November 2013, Vol 4, No 9
The Patient-Reported Outcomes Measurement Information System (PROMIS) tool can inform clinical care delivery for patients with cancer, according to the initial results of a National Institutes of Health (NIH)-funded project.
Read Article
Long-Term Cetuximab Therapy Shows Early Tumor Shrinkage in Colorectal Cancer
In the Literature
November 2013, Vol 4, No 9
In a new study, researchers analyzed data from 2 trials to determine if early tumor shrinkage was associated with long-term outcomes in patients with colorectal cancer receiving first-line treatment with cetuximab (Piessevaux H, et al.
J Clin Oncol
. 2013;31:3764-3775).
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma